Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. National Medical Care Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 10.42%.
National Medical Care Co (SAU:4005) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
National Medical Care Co (SAU:4005) has a ROCE % of 10.42% as of Mar. 2026.
Is National Medical Care Co's ROCE % too high?
National Medical Care Co's current ROCE % is 10.42%. The Healthcare Providers & Services industry median ROCE % is 6.41. National Medical Care Co's value of 10.42% is 62.6% above this industry median. Overall, National Medical Care Co has a GF Score™ of 94/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does National Medical Care Co's ROCE % compare to HCA and THC?
National Medical Care Co's ROCE % of 10.42% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. National Medical Care Co's value of 10.42% is 62.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 641 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. National Medical Care Co's current ROCE % of 10.42% is 62.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. National Medical Care Co's current ROCE % is 10.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is National Medical Care Co stock overvalued right now?
Based on GuruFocus' analysis, National Medical Care Co (SAU:4005) is currently considered Possible Value Trap. The stock's GF Value™ is ﷼210.40, compared to a current price of ﷼115.00 — trading 45.3% below its estimated fair value. The current ROCE % is 10.42% and 62.6% above the Healthcare Providers & Services industry median of 6.41. National Medical Care Co's overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For National Medical Care Co (SAU:4005), the current ROCE % is 10.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is National Medical Care Co (SAU:4005) Overvalued in 2026?
Based on GuruFocus' analysis, National Medical Care Co stock appears to be undervalued.
The current stock price of ﷼115.00 is trading 45.3% below its estimated GF Value™ of ﷼210.40.
GuruFocus considers National Medical Care Co to be Possible Value Trap.
Key valuation signals for SAU:4005:
ROCE %: 10.42%
GF Value™: ﷼210.40 vs. price of ﷼115.00 (45.3% below fair value)
Industry Position: 62.6% above the Healthcare Providers & Services median
No single metric tells the full story. See the SAU:4005 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
National Medical Care Co is engaged in the business to establish, own, equip, manage, maintain, and operate healthcare facilities and provide home health care services. The company trades medicines, medical equipment, and supplies in wholesale and retail trade. Geographically, all operations are conducted in the Kingdom of Saudi Arabia. The company generates revenue through the Rendering of clinical services, and the Sale of pharmaceuticals.
94GF Score
Get the complete analysis for SAU:4005
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4005 has been successfully added to your 
